D-0599-2018 Class III Terminated

Recalled by Novel Laboratories, Inc. — Somerset, NJ

FDA drug recall D-0599-2018 was initiated by Novel Laboratories, Inc. on Mar 5, 2018 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications The recall status is terminated (terminated Jun 8, 2020). Affected quantity: 134,364 bottles (4,030,920 tablets).

Recall details

Product Type
Drugs
Report Date
Mar 21, 2018
Initiation Date
Mar 5, 2018
Termination Date
Jun 8, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
134,364 bottles (4,030,920 tablets)

Product description

Lupin Hydrocodone Bitartrate and Homatropine Methylbromide Tablets, USP 5/1.5 mg Rx Only 30 Tablets Manufactured by: Novel Laboratories, Inc. Somerset, NJ 08873 Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, MD 21202 NDC 43386-118-03 UPC 343386118038

Reason for recall

Failed Impurities/Degradation Specifications

Distribution pattern

Nationwide

Code information

M16002A (02/2018); M16246A (04/2018); M16246B (04/2018); M16434A (07/2018); M16569A (10/2018); M17015A (01/2019); S700271 (04/2019);

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0599-2018
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0599-2018. Report a data issue: hello@regdatalab.com.